Personalized DNA Cancer Vaccine
Melanoma
About Neomatrix
Neomatrix is a private, preclinical-stage biotech focused on personalized cancer immunotherapy. The company has developed an integrated platform for identifying patient-specific tumor neoantigens and rapidly manufacturing synthetic DNA vaccines. With €1.5 million in new funding secured in late 2024 and backing from EU Horizon 2020, Neomatrix is advancing its regulatory development and preparing for clinical studies in melanoma and lung cancer, targeting a significant unmet need in oncology.
View full company profileAbout Neomatrix
Neomatrix is a private, preclinical-stage biotech focused on personalized cancer immunotherapy. The company has developed an integrated platform for identifying patient-specific tumor neoantigens and rapidly manufacturing synthetic DNA vaccines. With €1.5 million in new funding secured in late 2024 and backing from EU Horizon 2020, Neomatrix is advancing its regulatory development and preparing for clinical studies in melanoma and lung cancer, targeting a significant unmet need in oncology.
View full company profileTherapeutic Areas
Other Melanoma Drugs
| Drug | Company | Phase |
|---|---|---|
| ABD-3001 | Advanced Biodesign | Phase 1 |
| SUPLEXA | Alloplex Biotherapeutics | Phase 1 |
| AV-MEL-1 | AIVITA Biomedical | Phase 1B |
| Melanoma Immunotherapy | Vaccizone | Pre-clinical |
| Undisclosed RNA Immunotherapy | Epitopea | Pre-clinical |
| Melanoma Monitoring Solution | Oncobit | Commercial |
| Undisclosed Enhanced Antibody Program | Score Pharma | Pre-clinical |
| ASO for Melanoma | Carnation Therapeutics | Pre-clinical |
| Cannabics® MLN-33 | CNBX Pharmaceuticals | Preclinical |